Navigation Links
Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
Date:7/24/2012

mon method that has been used with opioid drugs in order to attempt to block their conversion into abusable forms of an opioid. Phase 1 studies demonstrated that NKTR-181 produced sustained and dose-dependent analgesic responses in healthy volunteers, a slower rate of CNS entry as measured by pupillometry, or contraction of the pupils, and an excellent tolerability profile. NKTR-181's Phase 1 clinical development program evaluated the molecule in approximately 180 healthy volunteers. 

"As a new mu-opioid analgesic molecule, NKTR-181 has the potential to transform the treatment of chronic pain by using a molecular approach to reduce the risk of traditional opioid therapy while preserving its analgesic benefit," said Robert Medve, MD, the company's Senior Vice President and Chief Medical Officer. "We are excited to be advancing this molecule into Phase 2 testing in chronic pain patients."

The NKTR-181 Phase 2 study uses a randomized withdrawal design, which includes a baseline period and a drug titration period followed by a randomized, placebo-controlled, double-blind phase of the study. The primary endpoint of the study will be the average change in a patient's pain score from baseline to the end of the double-blind, randomized treatment period. The study will enroll opioid-naive patients with osteoarthritis of the knee who are not getting adequate pain relief from their current non-opioid pain medication. Patients who qualify during the baseline period will enter a titration phase, during which they will be titrated on NKTR-181 tablets administered orally twice-daily until a dose is reached that provides a reduction of at least 20% in the patient's pain score as compared to the patient's own baseline. Patients that achieve this level of analgesia will then be randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for up to 25 days. Secondary endpoints of the st
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015   Heska Corporation (NASDAQ: HSKA ... of advanced veterinary diagnostic and other specialty veterinary products ... will present at the 16th Annual B. Riley & Co. ... The conference will be held May 12-14, 2015 at Lowes ... management will be available during the day on May 13 ...
(Date:5/1/2015)... 1, 2015 Braeburn Pharmaceuticals announced ... therapeutic focus beyond addiction and pain to ... Braeburn has acquired an implantable, six-month formulation ... for treatment of schizophrenia from Endo Pharmaceuticals. ... rights to other potential applications of the ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation (NYSE: ... continued business momentum and long-term growth strategies at a ... New York City . President and Chief Executive ... opportunities the company has to bring forward meaningful innovation ... markets and deliver shareholder value. "We ...
Breaking Medicine Technology:Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7
... 2011 The oncology market continues to be a ... all the aspects of successfully launching a new oncology ... supporting the oncology therapeutic area are constantly assessing the ... group. Best Practices, LLC, a leader in ...
... MUNDELEIN, Ill., April 19, 2011 Sysmex, a ... information systems technology, announced today an amended distributorship ... which automatically renews for up to four successive ... instruments including the Sysmex pocH-100 i™ , Sysmex ...
Cached Medicine Technology:Oncology Global Strategic Marketing Study Offers Chance for Resource Benchmarks 2Sysmex America Signs Distributorship Agreement With LABSCO 2
(Date:5/2/2015)... As a nonsurgical staple in the ... neck and décolleté, radiofrequency energy is proving to ... the success of vulvovaginal rejuvenation. In a pilot ... ThermiGyn’s Women’s Health Clinical Advisory Board Chairman Red ... temperature controlled radio frequency, specifically that of ThermiVa, ...
(Date:5/1/2015)... Texas (PRWEB) May 02, 2015 IDLife ... Texas, is proud to announce the addition of its ... Widerstrom is a life long athlete, growing up in ... passion after college by becoming a personal trainer and ... been the face of several TV shows highlighting her ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Jusuru International ... for the successful repositioning of its flagship nutritional supplement, ... brand with a new name, new logo, new packaging, ... Ethos Awards are designed to identify and promote programs ... best. , “DSA congratulates Jusuru International for their ...
(Date:5/1/2015)... 01, 2015 TROY Healthcare Solutions is ... Regional User Group (RUG) Conference in Atlanta, GA from ... User Group Conference provides a forum for client-to-client presentations, ... all aspects of electronic medical record operations, as well ... applications. , In addition to sponsoring the event, TROY ...
(Date:5/1/2015)... Ernst & Young (EY) has announced Melanie ... CSO, and Burak Sezen, Co-Founder & CTO of RowdMap, ... Of The Year® 2015 Awards in the Ohio Valley ... global leader in assurance, tax, transaction and advisory services ... top audit companies in the world. The awards program ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... one of the leading publishers in the fields of ... The Endocrine Society to co-publish a new journal, ... Hormonal cancers include two of the most deadly cancer ... addition to these cancers, Hormones & Cancer ...
... , CHICAGO, Aug. 27 For years, it was ... procedures to save teeth compromised by extensive decay, gum disease and ... said times have changed and patients should forego prolonged dental heroics ... , , "There really is no justification ...
... ... at ASHG 2009 Meeting in Honolulu, Hawaii -- October 20-24, 2009, Hawaii Convention Center ... Bethesda, MD (Vocus) August 27, ... in Honolulu, Hawaii to present their latest research findings at the 59th Annual Meeting ...
... ... is trying to identify some of the factors that play into a smoker,s decision to quit. ... Manhasset, NY (Vocus) August 27, 2009 ... you may get an equal number of different answers. Christine Metz, PhD, is a scientist at ...
... shows , THURSDAY, Aug. 27 (HealthDay News) -- Children ... overcome their allergy by drinking increasingly higher doses of ... from Johns Hopkins Children,s Center in Baltimore reported that ... immune systems to tolerate milk and other dairy products ...
... , WEST PALM BEACH, Fla., Aug. ... is has added a new module designed to help physicians manage ... service and employee motivation are two of the most important yet ... Beer. , , Leading this new module is ...
Cached Medicine News:Health News:Springer signs publishing agreement with the Endocrine Society 2Health News:Why Save Bad Teeth? Dental 'Heroics' Unnecessary and Failure Prone 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 2Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 3Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 4Health News:The American Society of Human Genetics Hosts 59th Annual Meeting 5Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 2Health News:Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response 3Health News:Milk Allergy Symptoms May Ease With Exposure 2
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: